The Value of Peripheral Blood Cell Ratios in Primary Membranous Nephropathy: A Single Center Retrospective Study

References

• Giannini G, Arend LJ. The prevalence of mesangial electron-dense deposits in PLA2R-positive membranous nephropathy. Nephron. 2022;146(2):167–171. doi:10.1159/000519912
   PubMedGoogle Scholar
• De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421–430. doi:10.1681/ASN.2016070776
   PubMed Web of Science ®Google Scholar
• Lerner GB, Virmani S, Henderson JM, et al. A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy. Kidney Int. 2021;100(2):289–300. doi:10.1016/j.kint.2021.03.028
   PubMedGoogle Scholar
• Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. 2015;26(2):302–313.
   PubMed Web of Science ®Google Scholar
• Ronco P, Plaisier E, Debiec H. The role of PLA2R antibody monitoring: what we know and what we don’t know. Nephrol Dial Transplant. 2021. doi:10.1093/ndt/gfab356
   Google Scholar
• Qu Z, Zhang MF, Cui Z, et al. Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy. Am J Nephrol. 2018;48(6):438–446.
   PubMed Web of Science ®Google Scholar
• Li W, Zhao Y. Prognostic value of phospholipase A2 receptor in primary membranous nephropathy: a systematic review and meta-analysis. Int Urol Nephrol. 2019;51(9):1581–1596.
   PubMedGoogle Scholar
• Gao S, Cui Z, Wang X, et al. Rituximab therapy for primary membranous nephropathy in a Chinese cohort. Front Med. 2021;8:663680.
   Google Scholar
• Lu H, Shen J, Sun J, et al. Efficacy and safety of rituximab in the treatment of idiopathic membranous nephropathy: a meta-analysis. Appl Bionics Biomech. 2022;2022:5393797.
   PubMedGoogle Scholar
• Muruve DA, Debiec H, Dillon ST, et al. Serum protein signatures using aptamer-based proteomics for minimal change disease and membranous nephropathy. Kidney Int Rep. 2022;7(7):1539–1556. doi:10.1016/j.ekir.2022.04.006
   PubMedGoogle Scholar
• Zhao Q, Dai H, Hu Y, et al. Cytokines network in primary membranous nephropathy. Int Immunopharmacol. 2022;113(PtA):109412. doi:10.1016/j.intimp.2022.109412
   PubMedGoogle Scholar
• Posul E, Yilmaz B, Aktas G, et al. Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis? Wien Klin Wochenschr. 2015;127(7–8):262–265.
   PubMed Web of Science ®Google Scholar
• Duman TT, Aktas G, Atak BM, et al. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci. 2019;19(1):1602–1606. doi:10.4314/ahs.v19i1.35
   PubMed Web of Science ®Google Scholar
• Balci SB, Aktas G. A comprehensive review of the role of hemogram derived inflammatory markers in gastrointestinal conditions. Iran J Colorectal Res. 2022;10(3):2–13.
   Google Scholar
• Aktas G, Sit M, Dikbas O, et al. Elevated neutrophil-to-lymphocyte ratio in the diagnosis of Hashimoto’s thyroiditis. Rev Assoc Med Bras. 2017;63(12):1065–1068.
   PubMed Web of Science ®Google Scholar
• Khalid A, Ali Jaffar M, Khan T, et al. Hematological and biochemical parameters as diagnostic and prognostic markers in SARS-COV-2 infected patients of Pakistan: a retrospective comparative analysis. Hematology. 2021;26(1):529–542. doi:10.1080/16078454.2021.1950898
   PubMed Web of Science ®Google Scholar
• Afsin H, Aktas G. Platelet to lymphocyte and neutrophil to lymphocyte ratios are useful in differentiation of thyroid conditions with normal and increased uptake. Ethiop J Health Dev. 2021;35(3):1–5.
   Web of Science ®Google Scholar
• Atak Tel BM, Kahveci G, Bilgin S, et al. Platelet to lymphocyte ratio in differentiation of benign and malignant thyroid nodules. Exp Biomed Res. 2021;4(2):148–153. doi:10.30714/j-ebr.2021267978
   Google Scholar
• Atak B, Aktas G, Duman TT, et al. Diabetes control could through platelet-to-lymphocyte ratio in hemograms. Rev Assoc Med Bras. 2019;65(1):38–42. doi:10.1590/1806-9282.65.1.38
   PubMed Web of Science ®Google Scholar
• Aktas G, Duman TT, Atak BM, et al. Irritable bowel syndrome is associated with novel inflammatory markers derived from hemogram parameters. Fam Med Prim Care Rev. 2020;22(2):107–110. doi:10.5114/fmpcr.2020.95311
   Web of Science ®Google Scholar
• Aktas G. Hematological predictors of novel coronavirus infection. Rev Assoc Med Bras. 2021;67(Suppl1):1–2. doi:10.1590/1806-9282.67.suppl1.20200678
   PubMedGoogle Scholar
• Catal O, Ozer B, Sit M, et al. The role of monocyte to lymphocyt ratio in predicting metastasis in rectal cancer. Ann Med Res. 2021;28(3):527–531. doi:10.5455/annalsmedres.2020.05.466
   Google Scholar
• Kocak MZ, Aktas G, Duman TT, et al. Monocyte lymphocyte ratio as a predictor of diabetic kidney injury in type 2 diabetes mellitus; The MADKID study. J Diabetes Metab Disord. 2020;19(2):997–1002. doi:10.1007/s40200-020-00595-0
   PubMed Web of Science ®Google Scholar
• Atak Tel BM, Bilgin S, Kurtkulagi O, et al. Frailty in diabetic subjects during COVID-19 and its association with HbA1c, mean platelet volume and monocyte/lymphocyte ratio. Clin Diabetol. 2022;11(2):119–126. doi:10.5603/DK.a2022.0015
   Web of Science ®Google Scholar
• Wang G, Sun L, Dong H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients. Clin J Am Soc Nephrol. 2021;16(5):727–735. doi:10.2215/CJN.11860720
   PubMed Web of Science ®Google Scholar
• Perna A, Ruggiero B, Podestà MA, et al. Sexual dimorphic response to rituximab treatment: a longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome. Front Pharmacol. 2022;13:958136. doi:10.3389/fphar.2022.958136
   PubMed Web of Science ®Google Scholar
• Hussain Y, Khan F, Alsharif KF, Alzahrani KJ, Saso L, Khan H. Regulatory effects of curcumin on platelets: an update and future directions. Biomedicines. 2022;10(12):3180. doi:10.3390/biomedicines10123180
   PubMedGoogle Scholar
• Koupenova M, Clancy L, Corkrey HA, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018;122(2):337–351. doi:10.1161/CIRCRESAHA.117.310795
   PubMed Web of Science ®Google Scholar
• Yeung J, Li W, Holinstat M, Isom LL. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev. 2018;70(3):526–548. doi:10.1124/pr.117.014530
   PubMed Web of Science ®Google Scholar
• Olumuyiwa-Akeredolu OO, Pretorius E. Platelet and red blood cell interactions and their role in rheumatoid arthritis. Rheumatol Int. 2015;35:1955–1964.
   PubMedGoogle Scholar
• Łukasik ZM, Makowski M, Makowska JS. From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders. Rheumatol Int. 2018;38:959–974.
   PubMedGoogle Scholar
• Gasparyan AY, Ayvazyan L, Mukanova U, et al. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Lab Med. 2019;39(4):345–357.
   PubMed Web of Science ®Google Scholar
• Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: a meta-analysis. Eur J Clin Invest. 2021;51(3):e13386.
   PubMedGoogle Scholar
• Seo IH, Lee YJ. Usefulness of complete blood count (CBC) to assess cardiovascular and metabolic diseases in clinical settings: a comprehensive literature review. Biomedicines. 2022;10(11):2697.
   PubMedGoogle Scholar
• Lu X, Kan C, Zhang R. Phospholipase A2 receptor is associated with hypercoagulable status in membranous nephropathy: a narrative review. Ann Transl Med. 2022;10(17):938.
   PubMedGoogle Scholar
• Kazan DE, Kazan S. Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathy. Eur Rev Med Pharmacol Sci. 2023;27(2):642–648.
   PubMedGoogle Scholar
• Tsai SF, Wu MJ, Chen CH. Low serum C3 level, high neutrophil-lymphocyte-ratio, and high platelet-lymphocyte-ratio all predicted poor long-term renal survivals in biopsy-confirmed idiopathic membranous nephropathy. Sci Rep. 2019;9(1):6209.
   PubMedGoogle Scholar
• Wen Y, Yan HR, Wang B, et al. Macrophage heterogeneity in kidney injury and fibrosis. Front Immunol. 2021;12:681748.
   PubMedGoogle Scholar